S2 Part 1: Processing and minor processing

Published Date: 16 Feb 2023

Dr. Jacob Sands and Dr. Jared Weiss talk about subtypes. ongoing clinical trials; sustained sustained response to treatment; And it is possible to use the word "cure" to treat a small breast cancer.

Read Full News

Latest News

HF With Improved Ejection Fraction

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

S2 Episode 6: A Futuristic Vision for Treating Myelofibrosis

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Radiofrequency Ablation: A First-Line Treatment Option

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

S2 Episode 5: DNA Repair and Replication Stress in Endometrial Cancer

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

May 09 2025 This Week in Cardiology

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Should All Newborns Be Screened for Congenital Hypothyroidism?

Drs Kaniksha Desai and Larry Fox discuss congenital hypothyroidism, including when to test and how to treat it.

Todays Updates

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Todays Updates

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Latest News

Heart Failure with Improved ejection fraction is characterized by previously reduced left ventricular ejection fraction (≤40%) that subsequently improves to >40%. This review highlight existing clinical gaps and proposes future research directions to refine risk stratification and therapeutic approaches for this evolving HF population.

What will the next decade bring for myelofibrosis care? Drs Jain and Pemmaraju explore futuristic therapies, earlier interventions, and smarter diagnostics.

Drs Kaniksha Desai and Iram Hussain discuss the use of radiofrequency ablation for the treatment of hyperthyroidism.

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

The controversial KETO-CTA study, tough decisions in subclinical AF, and another potentially huge benefit for GLP-1 agonist drugs are discussed by John Mandrola, MD, in this week’s podcast.

Drs Kaniksha Desai and Larry Fox discuss congenital hypothyroidism, including when to test and how to treat it.

News All Time

S2 Episode 2: Endometrial Cancer Disparities: Access to Care and Trials

Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.

S2 Episode 1: Hormonal Therapy Updates in Metastatic Endometrial Cancer

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and treat ER+ metastatic endometrial cancer.

Managing Familial Hypercholesterolemia in Primary Care

Familial hypercholesterolemia is often diagnosed late, and patients with the condition are significantly undertreated.

IgA Nephropathy: 5 Differential Diagnoses to Know

IgAN diagnosis is complex, and differentiation from other glomerulopathies is critical. Consider these five important differentials to ensure timely diagnosis and appropriate treatment.

Q&A: Are You Sure the Diagnosis Is IgA Nephropathy?

Arnold B. Alper, MD, discusses the IgA nephropathy differential diagnosis.

SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer

Dr Avan Armaghani discusses the clinical impact of several studies presented at SABCS.

Key Updates in Early Breast Cancer From SABCS 2024

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

More Than Hives: Discussing Chronic Spontaneous Urticaria

Dermatologists discuss common roadblocks in communicating with patients with chronic spontaneous urticaria, who often search for a cause they can fix for a condition lacking in community resources.

Cardiac Myosin Inhibitors: Is the Emperor Wearing Any Clothes?

A commentary on the need for better trials and long-term data for the myosin inhibitors aficamten and mavacamten in obstructive hypertrophic cardiomyopathy.

New Directions in Anemia and Related Disorders From ASH 2024

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Episode 6: HER2-Ultra-Low Breast Cancer

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

Growth Hormone and the Thyroid Gland: A Complex Relationship

Drs Kaniksha Desai and Laurence Katznelson discuss the complex relationship between growth hormone and the thyroid gland.

ACR 2024: Key Insights on Updated Lupus Nephritis Guidelines

Dr Bella Mehta reviews new guidance on frequent monitoring, triple therapy, early biopsy, and reduced steroids for better outcomes.

Episode 5: Sequencing of ADCs for Metastatic HER2-Low Disease

Kathy D. Miller, MD, and Stephanie L. Graff, MD, discuss sequencing of ADCs for metastatic HER2-low breast cancer including sequencing, toxicities, and clinical trials.

Glomerular Disease Highlights From ASN Kidney Week 2024

Glomerular disease highlights from ASN 2024 include data on atacicept benefits in IgA nephropathy, protein reduction from pegcetacoplan, and a possible new therapy for membranous nephropathy.

Thrombocytosis and Cancer Risk: Management in Primary Care

Dr Kevin Fernando discusses managing thrombocytosis and the risk for cancer in primary care.

Recommended News For You

How artificial intelligence could significantly improve the prognosis for cancer patients.

Advancing Health in Africa

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women

Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

Breast awareness: What to look for in your self-exam

Recommended Articles For You

The Latest Research on Chronic Granulomatous Disease and Promising New Treatments  

Decoding the Padua Score to Prevent Blood Clots in High-Risk Patients 

The Unseen Threat: Uncovering the Risks of Pancoast Tumor 

AI in Cancer Diagnostics and Imaging Interpretation 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast cancer patients' arms swell less after an effective lymph node transfer.

2.

A new device enhances liquid biopsy.

3.

Both DNA damage repair deficiency and non-Hodgkin lymphoma are the focus of LP-284.

4.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

5.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

1.

Studying Lactic Acid in Pediatric Tumor Microenvironments: Experimental Approaches Explored

2.

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research

3.

HKDC1 Protein: An Emerging Therapeutic Target in Colon Cancer

4.

Revolutionizing Oncology: AI in Radiology, Machine Learning in Pathology, and Deep Learning for Cancer Detection

5.

Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Efficient Management of First line ALK-rearranged NSCLC - Part II

2.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

4.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot